Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Express Scripts
McKinsey
Medtronic
Colorcon
Boehringer Ingelheim

Last Updated: January 26, 2023

CLINICAL TRIALS PROFILE FOR DYMISTA


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Dymista

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01794741 ↗ 3 Month Safety Study of Dymista Nasal Spray and Fluticasone Propionate in Children 4-11 Years of Age With Allergic Rhinitis Completed Meda Pharmaceuticals Phase 3 2013-02-01 This is a 3 month safety study of Dymista Nasal spray in children aged 4 to 11 years with allergic rhinitis
NCT01915823 ↗ Safety and Efficacy Trial of Dymista Nasal Spray in Children Ages 4 to 11 With Seasonal Allergic Rhinitis (SAR) Completed Meda Pharmaceuticals Phase 3 2013-07-01 The purpose of this study is to determine if Dymista nasal spray is better and safer than placebo in treating children ages 4 to <12 years old who have seasonal allergic rhinitis.
NCT02238353 ↗ AZELASTINE/FLUTICASONE (AZE/FLU) Nasal Spray on Symptom Control, Nasal Mediators and Nasal Hyperresponsiveness in Allergic Rhinitis (AR) Unknown status Universitaire Ziekenhuizen Leuven Phase 4 2014-10-01 Comparative analysis of the efficacy of intranasal MP29-02 (a novel formulation of azelastine and FP) has already been conducted in patients with moderate-to-severe seasonal AR. The combination formulation appeared to be superior in these patients with better symptomatic relief. However, objective analysis of the effect of this treatment on nasal mediators and/or nasal hyperreactivity has not yet been performed and would help in understanding the additional benefit of the combination treatment over monotherapy with nasal corticosteroids.
NCT02249663 ↗ Clinical Equivalence of Azelastine Hydrochloride and Fluticasone Propionate, 137/50 mcg Nasal Spray to Dymista™ Unknown status Teva Pharmaceuticals USA Phase 3 2014-08-01 To evaluate the therapeutic equivalence of a test formulation of Azelastine hydrochloride and Fluticasone propionate Nasal Spray to the reference listed drug, Dymista™ Nasal Spray in the relief of the signs and symptoms of Seasonal Allergic Rhinitis.
NCT02279563 ↗ A Study Comparing the Bioequivalence of Azelastine Hydrochloride and Fluticasone Propionate Nasal Spray (Apotex, Inc.) to That of Dymista™ Nasal Spray (Meda Pharmaceuticals, Inc.) in the Treatment of Seasonal Allergic Rhinitis Unknown status Apotex Inc. Phase 2 2013-12-01 This study is to evaluate the equivalence of generic Azelastine Hydrochloride and Fluticasone Propionate Nasal Spray with that of the marketed drug, Dymista™ Nasal Spray, in the treatment of seasonal allergic rhinitis, and to evaluate the safety and tolerability of generic Azelastine Hydrochloride and Fluticasone Propionate nasal spray compared with Dymista™ nasal spray.
NCT02402465 ↗ Evaluating Factors Involved in Dymista's Superior Clinical Efficacy to Fluticasone Propionate in the Treatment of Seasonal Allergic Rhinitis Unknown status University of Chicago Phase 4 2015-02-01 Dymista, a combined product containing the antihistamine azelastine and the intranasal steroid fluticasone, provides superior clinical efficacy to both fluticasone propionate and azelastine hydrochloride in the treatment of seasonal allergic rhinitis. The superiority of efficacy not only occurs at the initiation of treatment, but persists for its duration. The mechanism underlying the superior efficacy of Dymista is not known. This trial focuses on examining the effects of Dymista on the dynamics of the allergic response in man using nasal provocation with antigen. The investigators will study the relationship between symptoms, physiology, cells and mediators.
NCT02883439 ↗ Study to Analyse Difference in Bioavailability Between MP29-02 and Fluticasone Propionate Withdrawn MEDA Pharma GmbH & Co. KG N/A 2016-08-01 The aim of this study is to investigate and to compare the bioavailability of MP29-02 and fluticasone propionate in nasal tissue after nasal application. This may provide a rational basis for the use of 1 puff per nostril dosage regimen of the drugs. Clinical experience has demonstrated the efficacy of the twice-daily treatment; however, so far, no data are available on the local tissue concentrations of MP29-02 after topical application.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Dymista

Condition Name

Condition Name for Dymista
Intervention Trials
Seasonal Allergic Rhinitis 5
Allergic Rhinitis 5
Allergy 1
Asthma, Allergic 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Dymista
Intervention Trials
Rhinitis, Allergic 11
Rhinitis 11
Rhinitis, Allergic, Seasonal 6
Inflammation 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Dymista

Trials by Country

Trials by Country for Dymista
Location Trials
United States 41
China 18
Canada 2
Belgium 2
United Kingdom 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Dymista
Location Trials
Illinois 3
Pennsylvania 3
Minnesota 2
Alabama 2
Alaska 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Dymista

Clinical Trial Phase

Clinical Trial Phase for Dymista
Clinical Trial Phase Trials
Phase 4 5
Phase 3 4
Phase 2 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Dymista
Clinical Trial Phase Trials
Completed 4
Unknown status 4
Not yet recruiting 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Dymista

Sponsor Name

Sponsor Name for Dymista
Sponsor Trials
MEDA Pharma GmbH & Co. KG 3
Meda Pharmaceuticals 2
Apotex Inc. 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Dymista
Sponsor Trials
Industry 8
Other 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
Colorcon
Baxter
Mallinckrodt
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.